Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritisDavid Moulin, Marie Millard, Mahdia Taïeb, Chloé Michaudel, Anne Aucouturier, Antoine Lefèvre, Luis G Bermúdez-Humarán, Philippe Langella, Youssouf Sereme, Kristell Wanherdrick, Preeti Gautam, Xavier Mariette, Philippe Dieudé, Jacques-Eric Gottenberg, Jean-Yves JouzeauSee the full list of authors
24 November 2023
In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammationEleftheria Pertsinidou, Saedis Saevarsdottir, Vivek Anand Manivel, Lars Klareskog, Lars Alfredsson, Linda Mathsson-Alm, Monika Hansson, Martin Cornillet, Guy Serre, Rikard Holmdahl, Karl Skriner, Per-Johan Jakobsson, Helga Westerlind, Johan Askling, Johan Rönnelid
27 November 2023
Definition of rheumatoid arthritis flare based on SDAI and CDAIVictoria Konzett, Andreas Kerschbaumer, Josef S Smolen, Eirik Klami Kristianslund, Sella A Provan, Tore K Kvien, Daniel Aletaha
27 October 2023
Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studiesTeresa A Simon, Lixian Dong, Samy Suissa, Kaleb Michaud, Sofia Pedro, Marc Hochberg, Maarten Boers, Johan Askling, Thomas Frisell, Anja Strangfeld, Yvette Meissner, Vadim Khaychuk, Alyssa Dominique, Michael A Maldonado
6 November 2023
Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohortSascha Louise Heckert, Johanna Maria Maassen, S le Cessie, Y P M Goekoop-Ruiterman, Melek Güler-Yüksel, Willem Lems, Tom WJ Huizinga, Sytske Anne Bergstra, Cornelia F Allaart
18 November 2023
Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?Lotte van Ouwerkerk, Patrick Verschueren, Maarten Boers, Paul Emery, Pascal Hendrik Pieter de Jong, Robert BM Landewé, Willem Lems, Josef S Smolen, Tom WJ Huizinga, Cornelia F Allaart, Sytske Anne Bergstra
22 August 2023
Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritisVictoria Konzett, Andreas Kerschbaumer, Josef S Smolen, Daniel Aletaha
27 September 2023
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)Roy M Fleischmann, Désirée van der Heijde, Vibeke Strand, Tatsuya Atsumi, Iain B McInnes, Tsutomu Takeuchi, Peter C Taylor, Marguerite Bracher, David Brooks, John Davies, Christopher Goode, Anubha Gupta, Sumanta Mukherjee, Ciara O’Shea, Didier SaurignySee the full list of authors
12 September 2023
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)Peter C Taylor, Michael E Weinblatt, Iain B McInnes, Tatsuya Atsumi, Vibeke Strand, Tsutomu Takeuchi, Marguerite Bracher, David Brooks, John Davies, Christopher Goode, Anubha Gupta, Sumanta Mukherjee, Ciara O’Shea, Didier Saurigny, Lorrie A SchifanoSee the full list of authors
11 September 2023
Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based studyHo So, Tsz On Lam, Huan Meng, Steven Ho Man Lam, Lai-Shan Tam
24 July 2023
